CoChat

Emerging organoid models: leaping forward in cancer research

Open access
Fan, Han, Demirci, Utkan, Chen, Pu · 2019 · Journal of Hematology & Oncology

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

Cancer heterogeneity is regarded as the main reason for the failure of conventional cancer therapy. The ability to reconstruct intra- and interpatient heterogeneity in cancer models is crucial for understanding cancer biology as well as for developing personalized anti-cancer therapy. Cancer organoids represent an emerging approach for creating patient-derived in vitro cancer models that closely recapitulate the pathophysiological features of natural tumorigenesis and metastasis. Meanwhile, cancer organoids have recently been utilized in the discovery of personalized anti-cancer therapy and prognostic biomarkers. Further, the synergistic combination of cancer organoids with organ-on-a-chip and 3D bioprinting presents a new avenue in the development of more sophisticated and optimized model systems to recapitulate complex cancer-stroma or multiorgan metastasis. Here, we summarize the recent advances in cancer organoids from a perspective of the in vitro emulation of natural cancer evolution and the applications in personalized cancer theranostics. We also discuss the challenges and trends in reconstructing more comprehensive cancer models for basic and clinical cancer research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-019-0832-4

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Cancer organoids can be derived from patients with diverse cancer grades and subtypes. Patient-derived organoids can possess patient-specific genetic and epigenetic contexts for preclinical cancer research and theranostics. Meanwhile, normal organoids can be used to model cancer evolution after the introduction of oncogenic mutations. By using the time-lapse microscopic imaging, tumor cell behaviors can be monitored in real-time. Similar to cell lines, cancer organoid lines can be expanded and cryopreserved to establish a living organoid biobank
Fig. 1 Cancer organoids can be derived from patients with diverse cancer grades and subtypes. Patient-derived organoids can possess patient-specific genetic and epigenetic contexts for preclinical cancer research and theranostics. Meanwhile, normal organoids can be used to model cancer evolution after the introduction of oncogenic mutations. By using the time-lapse microscopic imaging, tumor cell behaviors can be monitored in real-time. Similar to cell lines, cancer organoid lines can be expanded and cryopreserved to establish a living organoid biobankCC BY · PubMed Central
Fig. 2 Patient-derived cancer organoids can be derived from surgically resected/biopsied tissues and circulating tumor cells. Additionally, using the gene-editing technique, normal organoids can be mutated into tumor organoids
Fig. 2 Patient-derived cancer organoids can be derived from surgically resected/biopsied tissues and circulating tumor cells. Additionally, using the gene-editing technique, normal organoids can be mutated into tumor organoidsCC BY · PubMed Central
Fig. 3 a A vascularized organ-on-a-chip model was utilized to analyze BC cell invasion and metastasis through a microvascular network. b A multi-organ-on-a-chip system was composed of a “primary site” and three “main sites of metastatic”. This microfluidic system was used to model lung cancer metastasis to distant organs, which provided an experimental platform to analyze cell-microenvironment interactions in organ-specific metastasis. c Schematic diagram of the 3D bioprinting technology for organ-on-a-chip models. d An extrusion-based bioprinting platform that interrogates the paracrine loop between BC cells and macrophages in different geometric arrangement. An extrusion-based 3D bioprinting technique for constructing breast cancer metastasis model. e Fabrication of the 3D HeLa/hydrogel spheroids by 3D printing
Fig. 3 a A vascularized organ-on-a-chip model was utilized to analyze BC cell invasion and metastasis through a microvascular network. b A multi-organ-on-a-chip system was composed of a “primary site” and three “main sites of metastatic”. This microfluidic system was used to model lung cancer metastasis to distant organs, which provided an experimental platform to analyze cell-microenvironment interactions in organ-specific metastasis. c Schematic diagram of the 3D bioprinting technology for organ-on-a-chip models. d An extrusion-based bioprinting platform that interrogates the paracrine loop between BC cells and macrophages in different geometric arrangement. An extrusion-based 3D bioprinting technique for constructing breast cancer metastasis model. e Fabrication of the 3D HeLa/hydrogel spheroids by 3D printingCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Research works printed but not linked: 1

  1. Society AC. Global Cancer Facts & Figures 3rd Edition. Am Cancer Soc. 2015;800:1–64.

Cited by

See all 199

Metadata

Authors
Fan, H., Demirci, U., & Chen, P.
Affiliations
  • Stanford Medicine (US)
  • Wuhan University (CN)
Corresponding author
  • Demirci, Utkan
  • Chen, Pu
Venue
Journal of Hematology & Oncology
Published
2019-12
Volume
12
Issue
1
Pages
142-142
ISSN
1756-8722 (ISSN-L)
OpenAlex
W2997819890
Cited by
199
References
71
Citations by year
2026: 10 · 2025: 23 · 2024: 27 · 2023: 17 · 2022: 40 · 2021: 55 · 2020: 26
FWCI
2.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Key Research and Development Program of China (2018YFA0109000)
  • Applied Foundational Research Program of Wuhan Municipal Science and Technology Bureau (2018010401011296)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
tumor organoids, patient-derived tumor models, tumor heterogeneity, precision oncology, organ-on-a-chip, 3D bioprinting, metastasis, tumor microenvironment, prognostic factors, cancer theranostics, in vitro tumor model
MeSH terms
Animals, Drug Evaluation, Preclinical, Humans, Models, Biological, Neoplasms, Organoids, Tissue Engineering, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging organoid models: leaping forward in cancer research. https://app.cochat.ai/papers/10.1186/s13045-019-0832-4
The paper
Fan, H., Demirci, U., & Chen, P. (2019). Emerging organoid models: leaping forward in cancer research. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-019-0832-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.